Plus Therapeutics 2025 net loss widens

Cerenome

12/03/2026 21:26

Overview

U.S. radiopharmaceutical developer reported 2025 net loss widened to $22.4 mln

Operating loss for 2025 widened

Outlook

Company expects R&D expenditures to increase in 2026 due to expanded clinical trials and manufacturing

Result Drivers

CNSIDE TEAM EXPANSION - Co said higher operating loss was mainly due to expansion of CNSide operations team

DERIVATIVE INSTRUMENTS - Co said change in net loss was primarily due to change in fair value of derivative instruments from Q1 2025 financings

Company press release: ID:nGNXbzwtlv

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
FY Net Income
-$22.39 mln
FY Operating Expenses
$20.51 mln
FY Operating Income
-$15.30 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Plus Therapeutics Inc is $2.00, about 550% above its March 11 closing price of $0.31

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)